Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance is a research paper published in PLoS ONE (2020). On theSindex it has a DataRank of 0. It has been cited 8 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R35 CA231998
National Institutes of Health
Grant: R01 DE024728
National Institute of Dental and Craniofacial Research
Grant: F31 DE026951
NCI NIH HHS
Grant: P50 CA097190
NCI NIH HHS
Grant: U54 CA209891
National Institutes of Health
Grant: 5R01DE024728-04
Implications of Procaspase-8 Mutations in Oral Squamous Cell Carcinoma
National Institutes of Health
Grant: 1F31DE026951-01A1
Targeting the IL-6 pathway in combination with cetuximab in head and neck squamous cell carcinoma
National Institutes of Health
Grant: 5R35CA231998-04
Integrating genomics and the protein interactome for HPV+ head and neck cancer therapy
FWCI
0.66
Citation Percentile
0.7%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals